CDC seeks to protect older adults with shingles vaccine message by Centers for Disease Control and Prevention (U.S.)
 
For More Information: 
At CDC:  
Curtis Allen, 404-639-8487 
callen@cdc.gov  
At National Association of Chronic Disease Directors: 
Jeanne Alongi, 916-452-2440 
alongi@chronicdisease.org  
At CDC Healthy Aging Program: 
Maggie Moore, 770-488-5598 
mmoore6@cdc.gov
At Health Benefits ABCs: 




CDC Seeks to Protect Older Adults 
  With Shingles Vaccine Message 
“Shingles is an illness that really decreases the quality of life for senior citizens.  
The good news is that there is a vaccine that can help maintain their quality of life at a higher 
standard.” — Dr. Martin Myers, National Network for Immunization Information 
 
Did you know…? 
√  There are about a million new cases of shingles each year in the United States. 
√ Anyone who has had chicken pox can get shingles. That means 95% of adults are at risk.  
√ Approximately one-third of the U.S. population will get shingles. The risk rises after 50 years of 
age. Half of people living to age 85 have had or will get shingles.  
√ More than half of older adults do not understand the seriousness of shingles and its complications.  
√ Among those who get shingles, more than one-third will develop serious complications. The risk 
of complications rises after 60 years of age. 
√ Prompt treatment is essential to control acute symptoms. 
√ There is a new vaccine that can lower the risk of getting shingles. 
 
 Shingles — an extremely painful and debilitating rash that can lead to even more severe 
complications — has been called “the scourge of the elderly” (Wood, 1995). What if there were a vaccine 
with few side effects that could cut in half the chance of an older adult getting shingles and, perhaps more 
importantly, reduce the severity of complications? Wouldn’t every eligible older adult in America roll up 
his or her sleeve to receive the vaccine? 
 Such a product — Zostavax (“Zos-tah-vax”), an injectable vaccine, has been licensed by the Food 
and Drug Administration (FDA) and recommended for one-time administration to most adults age 60 or 
older by the Centers for Disease Control and Prevention (CDC). The Census Bureau estimates there are 
50.6 million people age 60 or older in the United States. Yet only 1 million doses of Zostavax were 
distributed in the first year the vaccine was on the market (through the end of June 2007), according to its 
manufacturer, Merck & Co., Inc. This underscores how vital it is to educate both physicians and 
consumers about the seriousness of shingles as a painful and debilitating disease, and the importance of 
the shingles vaccine. 
 
WHAT IS SHINGLES? 
“Shingles is a very different kind of disease than the ones we usually talk about. It is a reactivation  
of a disease rather than a new infection.”  — Megan Lindley, CDC Immunization Services Division 
 
 The disease known as shingles (also called herpes zoster) occurs when the varicella-zoster virus 
(VZV) — the same virus that causes chickenpox — is reactivated in the body. Like all herpes viruses, 
VZV remains in the body for life. Even after a child recovers from chickenpox, the virus remains dormant 
in the nerve roots (dorsal root ganglia). As a person’s immunity to VZV begins to decline at the cellular 
level at older ages, the VZV virus can travel back up the nerve and reach the skin, causing the painful rash 
known as shingles. The blistering rash is usually limited to a small area on one side of the body, often on 
the face or torso. Shingles also can produce typical virus symptoms: chills, fever, upset stomach or 
headache.  
 A typical case of shingles might go like this: An active 62-year-old person —who plays tennis 
three times a week, volunteers in the community and is socially active — develops a rash on one side of 
the chest. The skin becomes red, blistered and painful. The rash occurs in a band-like area, which is the 
region supplied by the particular involved nerve. Clusters of small bumps become fluid-filled blisters, 
which later drain and form crusted scabs. The weight of clothing or a passing breeze can cause agony. 
Even sitting, sleeping and eating are aggravating if those activities put pressure on the sores. The patient 
needs to get to a doctor to receive anti-viral medicine as soon as possible. Anti-viral medications can 
reduce the severity and duration of shingles, but do not prevent the development of postherpetic 
neuralgia, which is responsible for much of the severe illness of shingles in older adults (Oxman, 2005). 
Anti-virals have been shown to reduce other complications, such as those involving the eye (ophthalmic 
herpes zoster). The rash may continue for two to four weeks, but eventually improves and the pain 
diminishes. The person then returns to a normal schedule. 
 For other people who develop shingles, the story is different. They develop chronic pain and 
serious complications that make it difficult to sleep, leave the house or shop (Katz, 2004; Schmader, 
2007). Sometimes they never return to normal activities, and become depressed and reclusive because of 
long-term pain and disability.  
 Complications develop in somewhere between one-third and one-half of older adults with shingles; 
the percentage rises with the age of the person in whom shingles develops (Insinga, 2007; Oxman, 2005). 
The most frequent complication is the chronic pain syndrome called postherpetic neuralgia (PHN). PHN is 
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the occurrence of persistent pain after the shingles rash heals; it can last for months or even years. Only 
rarely does PHN cause disability and suffering for the rest of the patient’s life.  
 Studies of pain severity have shown that the long-term pain of PHN exceeds pain scores for 
childbirth, musculoskeletal pain, osteoarthritis and chronic cancer pain (Katz, 1999). In one study, 42% of 
patients referred to their worst shingles pain as “horrible” or “excruciating” (Katz, 2004). As pain levels 
increase, the person is more likely to have a decline in physical and social functioning and an increase in 
emotional distress (Katz, 2004). Patients with more severe pain during the initial stage of shingles may be 
at higher risk for developing PHN (Wood, 1995). 
 Research puts shingles and postherpetic neuralgia on a par with congestive heart failure, diabetes and 
depression for disrupting a person’s quality of life (Lydick, 1995). Thus, shingles can have a major impact on 
morbidity, lost work productivity and quality of life in older adults (Hornberger, 2006; Oxman, 2005).  
 “Shingles can really blight the lives of older people,” commented Michael Oxman, MD, Study 
Chairman of the Department of Veterans Affairs’ (VA) Shingles Prevention Study and Professor of 
Medicine and Pathology, University of California, San Diego and Staff Physician (Infectious Diseases) at 
the VA San Diego Healthcare System. “I have seen active people end up in a nursing home due to PHN,” 
Dr. Oxman said. 
 In addition to the excruciating pain of PHN, other complications of shingles may include scarring, 
secondary bacterial infections, pneumonia, visual and hearing impairments and, rarely, death. If left 
untreated, 10% of patients whose shingles affects an eye will experience severe visual loss, eyelid 
scarring or chronic in-turning of the eyelashes (Severson, 2003). 
 Although shingles is not highly communicable, it is a public health concern because of the serious 
complications, the detrimental impact on quality of life and the cost of care. The Agency for Healthcare 
Research and Quality recently estimated that an average of $566 million per year is spent on health care 
for shingles and its complications (AHRQ, 2007). Another study estimated that the overall costs of 
shingles and PHN may be as high as $1.7 billion a year, including health care costs and productivity 
losses (Dworkin, 2007).  
 The AHRQ report, using data from the 2003-2005 Medical Expenditure Panel Survey, found that 
the average expenditure for shingles-related treatment was $525 per person, including $317 for visits to 
physicians and $157 for prescription medicines. Among those age 65 and older with shingles, the AHRQ 
analysis found that 40.2% of expenditures for shingles treatment were made by Medicare, 29.3% by 
individuals and 21.2% by private insurers. 
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WHO GETS SHINGLES? 
 Shingles affects an estimated 1 million or more individuals in the United States each year — 
almost half of those cases are among people age 60 or older, for whom zoster vaccine is recommended 
(Oxman, 2005).  
 “Anyone who has ever had chicken pox … is at risk for shingles,” explained Joan Benson, MD, 
MPH, Executive Director for Policy, Public Health and Medical Affairs for Global Vaccines and 
Infectious Disease at Merck & Co., Inc. Studies show that over 95% of all adults have had chickenpox, 
even if they do not recall the chickenpox episode (Kilgore, 2003). 
 Experts estimate that somewhere between 20% and 30% of people develop shingles over their 
lifetime (Schmader, 2002). Because risk rises with age, by age 85 approximately 50% of adults that old 
have had or will have shingles (Schmader, 2002). In addition, older adults are more likely than younger 
adults to have a more severe case of shingles and to develop PHN (Oxman, 2005). 
 It is not clear why some people develop shingles and others do not, but it appears to be connected 
to immunity. The risk for getting shingles begins to rise around age 50, because older adults tend to have 
weaker immune systems. People more likely to get shingles also include those with HIV infection or 
cancer, or those who are receiving chemotherapy, radiotherapy, immunosuppressant drugs or 
corticosteroids (steroids).  
 “The predominance of epidemiological data shows shingles is more common among women, and 
that is controlling for age and the fact that women live longer,” said Rafael Harpaz, MD, MPH, an 
epidemiologist with CDC’s National Center for Immunization and Respiratory Diseases. One study found 
60% of the people who got shingles were women and 40% were men (Insinga, 2005).  
 Studies conducted in the United States and the United Kingdom indicate that shingles are less 
common in the black population than among whites, Dr. Harpaz said. 
 
HOW IS SHINGLES TREATED?  
“The anti-viral drugs generally don’t have many interactions and they are only  
taken for a transient period of time.” — Dr. Ken Schmader, Duke University 
 
 Most cases of shingles can be managed in the primary care setting, but specialists are sometimes 
required if the eyes, lungs or other organs are involved, or if a pain specialist is needed.  
 Appropriate and immediate treatment of herpes zoster can control acute symptoms and reduce the 
risk of longer term complications. Starting anti-viral medication within 72 hours of the onset of shingles 
can reduce the pain and the length of time the outbreak lasts. Anti-viral medicines used to treat shingles 
include acyclovir (Zovirax), famciclovir (Famvir) and valacyclovir (Valtrex). Topical antibiotics may be 
prescribed if the blisters become infected. A medicated lotion (such as Benadryl or Caladryl) or astringent 
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soaks (such as Bluboro or Domeboro) may relieve pain and itching, according to the American Academy 
of Family Physicians. Pain medicine (analgesics or opioids) also may be prescribed for shingles or PHN. 
 While anti-viral drugs are generally well-tolerated by older adults, “the more difficult problem 
occurs when older adults are being treated for pain and prescribed analgesics,” according to Kenneth 
Schmader, MD, a geriatrics professor at Duke University who is also the co-investigator for the Shingles 
Prevention Study, a VA Cooperative Study Program that looked at the efficacy of a shingles vaccine. 
“There, things get trickier,” Dr. Schmader said. “Opioids can have a terrific amount of side effects in 
older adults, such as dizziness, constipation, nausea, vomiting, and they have to be prescribed pretty 
carefully.” These drugs also could interact with other medications affecting the central nervous system, 
such as anti-depressants, anti-psychotics or benzodiazepines, explained Dr. Schmader. 
 Shingles cannot spread to cause other cases of shingles in exposed persons. However, the shingles 
rash does contain VZV, which can be transmitted to cause chickenpox in persons (mostly younger 
children) who have never had chickenpox or never been vaccinated with the varicella vaccine. Shingles is 
considerably less contagious than chickenpox, and it is generally not necessary to isolate the affected 
person while the rash is present. Covering the rash with dressings or clothes can reduce the risk of 
transmission further. 
 
THE VACCINE FOR PREVENTING SHINGLES 
“Shingles is a very prevalent disease, is more common among older adults, and is more serious as 
you age. So we are really concerned that older adults get vaccinated as soon as possible before 
they are at risk for serious complications of the disease.” — Megan Lindley, CDC  
 
 Fortunately, researchers have developed a preventive vaccine, Zostavax, sold by Merck. Zostavax 
is a live, attenuated vaccine, meaning it is a living organism that has been weakened and adapted to 
provide immunity without causing illness. Researchers believe the vaccine works by boosting VZV-
specific immunity. Zostavax is a stronger version of the same varicella vaccine that is given to children to 
prevent chicken pox. It is important to point out that the vaccine is for preventing, not treating, shingles.  
 Approved by the FDA in May 2006, Zostavax is licensed as a one-dose vaccine for people age 60 
years or older. The federal Advisory Committee on Immunization Practices (ACIP), an advisory body to 
CDC, voted in October 2006 to recommend the vaccine. Those recommendations will be published 
shortly in Morbidity and Mortality Weekly Report (MMWR). ACIP recommendations become official 
CDC policy when published in the MMWR.  
 “Zostavax is about 50% effective in preventing shingles, but the exciting thing for me as an older 
person myself is that it reduces my chance of having shingles and it reduces my chance of having PHN, 
which is the awful complication of shingles,” said Martin Myers, MD, director of the National Network 
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for Immunization Information in Galveston, Texas. “My wife and I were at the head of the line to get the 
vaccine,” he added. 
 Research clearly shows that adults age 60 or older can have a significant benefit from the 
Zostavax vaccine (Oxman, 2005; Pellissier, 2007). Based on the findings of the Shingles Prevention 
Study, a large clinical trial that tested Zostavax versus placebo in 38,000 adults who were age 60 years or 
older, the vaccine reduced:  
• the overall incidence of shingles in older adults by about 51% and 
• the incidence of PHN by 67%. 
 The study also found that the vaccine’s effectiveness in reducing the incidence of shingles drops 
with the age of the vaccine recipient. For example, Zostavax was 64% effective for those age 60-69 years, 
41% effective for those ages 70-79 years and 18% effective for those age 80 years or older. However, the 
number of cases of shingles and PHN among people age 80 or older is so high that vaccinating this 
population “actually has major impact,” Dr. Harpaz said, particularly since the effectiveness of the 
vaccine at preventing PHN is better maintained in persons age 80 and older. Indeed, the oldest adults are 
most likely to suffer detrimental effects from shingles and PHN. They have a harder time seeking and 
obtaining medical care to obtain anti-viral or pain medication. Furthermore, they tend to be frailer, with 
multiple chronic conditions and “they are least able to tolerate PHN and the powerful medications used to 
treat the pain of PHN,” Dr. Harpaz said. “People of this age have little reserve, and are least able to 
handle the debilitating effects of shingles and PHN.” 
 Considering how severely shingles can impact people, and the vaccine’s reduction of the risk of 
developing PHN, this is considered an important vaccine for older adults of all ages.  
 
PRESCRIBING THE VACCINE 
 “The vaccine is more effective in people ages 60-69, so it is probably better that they get 
vaccinated at that age,” said Megan Lindley, MPH, coordinator of the Shingles Vaccine Implementation 
Group in CDC’s Immunization Services Division. “Although it is not 100% effective, shingles is so 
common that having people vaccinated against the disease should have a profound effect on public 
health.” 
 There are no contraindications for most older people with existing chronic disease who may be 
taking medications. “There is no problem giving the vaccine to older people who are on multiple 
medications,” explained Dr. Schmader. “The only concern is that individuals who are on 
immunosuppressant agents, like high-dose prednisone or cancer chemotherapy, should not be getting the 
shingles vaccine.” The vaccine should not be given to people who have immunodeficiencies due to AIDS, 
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leukemia, lymphoma or malignant neoplasms affecting the bone marrow or lymphatic system. It is also 
not recommended for women who are pregnant. 
 Frailty alone is not a barrier to getting the vaccine. “The issue here is that the people in frailest 
health are also the people most at risk for complications of zoster and so to my knowledge there is not a 
contraindication for people who are frail, unless they have immunocompromising conditions,” said 
Walter Orenstein, MD, director of the Emory University’s Program for Vaccine Policy and Development. 
 It is considered safe to get Zostavax at the same time as an influenza vaccination (Kerzner, 2007). 
 As with most vaccines, common side effects include mild reactions (discomfort, swelling or 
redness) at the injection site, headache or itching. No serious problems have been identified from the 
shingles vaccine, CDC said. 
 Zostavax is being closely monitored for unusual or severe problems, as are all vaccines. A post-
marketing study will continue to assess whether more serious adverse events occur more frequently 
among those who received the vaccine. Vaccine recipients should report to their doctor if anything 
unusual happens immediately following vaccination, including allergic reactions (difficulty breathing, 
wheezing or hives), a high fever or behavior changes. If someone does experience a serious reaction, they 
should ask their doctor or nurse to report it by filing a Vaccine Adverse Event Reporting System 
(VAERS) form, or an individual can file a report online by going to www.vaers.hhs.gov or calling 1-800-
822-7967. 
 
PAYING FOR THE VACCINE 
 Merck sells the vaccine to health care providers for $161.50 for a single dose, or $1,539 for 10 
doses. Physician administration fees and other charges can bring the price for consumers to somewhere 
between $165 and $300 per vaccination. That is substantially more than older adults are used to paying 
for an influenza or pneumococcal vaccine. Adult vaccine costs are approximately $11 to $15 for 
influenza, $24 for pneumococcus, $180 for the three-dose series of hepatitis B, $120 for the two-dose 
series of hepatitis A and $134 for the two-dose series of varicella. Merck said it conducted an extensive 
health economics analysis to help establish an appropriate price for Zostavax. 
 The Medicare Part B program, which covers part of the costs of care by physicians, outpatient 
hospitals, home health agencies and other health services for older adults, generally does not offer 
vaccines for preventing diseases. The only exception has been the vaccines for influenza, pneumococcal 
disease, and hepatitis B for those at increased risk. Those three vaccines were written into Medicare Part 
B law by Congress. Congress has not passed a law adding Zostavax to the list. The Partnership for 
Prevention, a public health policy organization, has recommended that Congress give the Medicare 
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program authority to add and remove coverage for preventive services without waiting for congressional 
action. 
 Starting in 2008, Congress required all Medicare Part D prescription drug plans, which are 
administered by private contractors, to include all commercially available vaccines not covered by Part B. 
“The vaccine should be on all Part D formularies in 2008,” said Jeffrey Kelman, MD, MMSc, Chief 
Medical Officer of the Center for Beneficiary Choices at the Centers for Medicare and Medicaid Services 
(CMS). However, Part D participants may have to meet a plan’s requirement for deductibles or 
copayments, and coverage may vary depending on what stage of prescription drug coverage (initial 
coverage period, gap or “donut hole,” catastrophic coverage) they are in. Starting in 2008, vaccine 
administration fees also are covered under Part D. 
 Older adults who get their prescription drug coverage through a Medicare Advantage Prescription 
Drug Plan also will be able to obtain vaccines under their plans, Dr. Kelman said.  
 Both Dr. Orenstein and Dr. Schmader said that coverage for Zostavax should be in Medicare Part 
B, not Part D. “But that is unlikely to happen,” Dr. Schmader added. “It takes an act of Congress to get 
something into Part B.” Putting Zostavax under Part D means that physicians have to get used to a 
different reimbursement system than they are accustomed to for vaccines covered under Medicare Part B.  
 Dr. Kelman outlined three ways that providers can be reimbursed for providing vaccines to older 
adults with Part D prescription drug coverage:  
 1) An in-network provider can charge the Part D plan for the vaccine and administration. 
 2) An out-of-network physician can bill the beneficiary, who must seek reimbursement from the 
Part D plan, or the physician can use a new Medicare Web portal device, which offers Web-assisted 
electronic physician billing to Part D plans. 
 3) A specialty pharmacy can send the vaccine to a physician’s office and the pharmacy then bills 
the Part D plan for the vaccine and the physician bills Part D for the administration fee.  
 For those adults not yet old enough to receive Medicare, some state Medicaid programs will 
cover the vaccine for low-income people who are ages 60-64. Private insurance plans may also cover the 
vaccine for beneficiaries 60-64 years old who do not qualify for Medicare. 
 For other low-income adults without insurance, Merck offers a vaccine assistance program 
(contact: 1-800-293-3881 or go to http://www.merckhelps.com). 
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GETTING MORE PEOPLE VACCINATED 
“Any new vaccine has a gradual uptake. It takes awhile for people to start thinking about it.” 
 — Dr. Martin Myers, National Network for Immunization Information 
 
 So why haven’t more older adults received Zostavax? Like many medical issues, the answer is 
complex. Part of the reason is that shingles is not highly communicable, rarely causes death and is not 
viewed by many as a major public health problem. In addition to cost issues outlined above, other barriers 
to vaccination involve the relative newness of Zostavax, the need for physician and public awareness and 
education about the vaccine, a medical system currently focused mostly on childhood vaccines, the need 
to keep Zostavax frozen until injected and, some say, the wording of the FDA package insert. 
 Education Issues. One key barrier for use of Zostavax is that physicians are not accustomed to 
new vaccines for adults. “This is the first new adult vaccine in a long time,” CDC’s Dr. Harpaz said. 
Compounding the vaccine’s newness is its modest effectiveness for reducing the incidence of shingles. 
Some older adults, and their physicians, may feel the vaccine is not worth bothering with, particularly as 
compared to pediatric vaccines which are typically much more effective. However, the shingles vaccine is 
about as effective for older adults as the influenza vaccine, which is widely utilized. “Physicians do not 
always appreciate the seriousness and potential severity of shingles, which can impact the strength of their 
recommendations to patients,” Dr. Benson noted. 
 The public also appears unaware of the serious nature of shingles. Two recent surveys — one 
conducted for the International Federation on Aging and the other for the American Pain Foundation 
(with funding from Merck) — found that many older adults (age 50+) do not know much about shingles. 
Among the startling findings of these two surveys: 1) Three-quarters of the respondents said that they 
knew only “some” (24 percent), “a little” (27 percent) or “almost nothing/not sure” (26 percent) about 
shingles. 2) About 50% of respondents did not consider themselves at risk for developing shingles despite 
having had chicken pox as a child. 3) About 40% said they would not take any immediate action if they 
had the initial signs of shingles, and half were unaware that there were medications to treat shingles. 4) 
About 60% of respondents were unaware that shingles can lead to chronic pain in some individuals.  
 “Unfortunately, the majority of consumers do not feel at risk for shingles,” Dr. Benson said. 
“This lack of disease awareness among consumers can impact their decisions to seek out preventative 
measures through vaccination.” 
 To help educate the public about shingles and Zostavax, Merck launched an education campaign 
via print media, the Internet and physician offices, and created a consumer website (Shinglesinfo.com). 
Merck also provided financial support for the American Pain Foundation’s public education campaign, 
“Spotlight on Shingles: Know What You Can Do.” Other partners in that campaign include the Alliance 
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for Aging Research, Assisted Living Federation of America, National Council on Aging and Older 
Women’s League. 
 For its part, CDC’s National Center for Immunization and Respiratory Diseases has developed 
fact sheets, posters and up-to-date Frequently Asked Questions by physicians and the public featured on 
its vaccine website. This information will be distributed through partnership organizations and 
immunization program managers, as well as sent out on a listserv called “Immunization Works” for 
organizations interested in immunization issues. CDC also partners with the Immunization Action 
Coalition, which works to increase immunization rates through public education.  
 Infrastructure Issues. Another barrier to vaccination is the absence of an adult immunization 
infrastructure similar to that for children, said Dr. Myers, who also is the Director for Public Health 
Policy and Education of the Sealy Center for Vaccine Development at the University of Texas Medical 
Branch.  
 There are relatively few vaccines for older adults anyway, “so this is a big breakthrough to have a 
new vaccine to address another important problem in older adults,” Dr. Schmader said. 
 Asked why society seems to be better at vaccinating children than older adults, Dr. Orenstein 
cited several reasons. 1) The vaccines used in adults generally are not as effective as those used for 
children, partly due to the more robust nature of children’s immune systems. 2) Childhood vaccines are 
built into a routine schedule for “well child” visits. 3) There is no financial safety net for adult vaccination 
that is similar to the Vaccines for Children Program or funding from Section 317 of the Public Health 
Service Act, which provides grants for immunizing children who cannot afford vaccines. 4) The diseases 
against which adults are vaccinated, with the exception of zoster, may not be easily distinguishable from 
similar clinical illnesses that are caused by other infectious agents. That makes the benefits of vaccines 
more difficult to appreciate.  
 In addition, the National Immunization Surveys conducted by CDC to track vaccination coverage 
are largely focused on children, not adults. Vaccines designed only for older adults (such as 
pneumococcal polysaccharide and Zostavax) also lack a national Vaccine Injury Compensation Program 
(VICP) like that available for children’s vaccines. VICP is a no-fault compensation program to resolve 
vaccine injury claims by providing compensation to people found to be injured by certain vaccines. 
According to Orenstein, CDC is considered a national leader on immunization issues; however, limited 
resources have resulted in a focus primarily on childhood immunization (Hinman, 2007). 
The National Vaccine Advisory Committee — which is an advisory body to the National Vaccine 
Program Office at the U.S. Department of Health and Human Services — has called for expanding 
Section 317 to adult immunization programs and creating a Vaccines for Adults Program to ensure adults 
have access to recommended vaccines.  
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 The Partnership for Prevention, in Strengthening Adult Immunization: A Call for Action, also 
called for programs and support for adult immunization. Those recommendations have been endorsed by 
the American Medical Association, American Public Health Association and other groups. 
 Vaccine Storage Issues. Another potential barrier to widespread use of the vaccine is the 
requirement that Zostavax must be kept frozen (5° F/-15°C or colder) when it is transported and stored, 
diluted just prior to administration and discarded if unused within a half-hour of preparing the vaccine. 
Not all primary care physicians have an appropriate freezer that is separate from a refrigerator. For offices 
without a free-standing freezer, Merck encourages physicians to refer appropriate patients to a pharmacy 
participating in the Merck Adult Vaccination Program, which allows pharmacists to provide vaccines 
where allowed by state law. 
 Meanwhile, Merck is working to develop a refrigerator-stable version (4°C) of the vaccine. 
 Package Label. FDA and ACIP (the advisory body to CDC) differed in some aspects of their 
recommendations about Zostavax. The ACIP said the vaccine should be given to people age 60+ 
regardless of whether or not they had a prior case of shingles. However, the package label approved by 
FDA states that Zostavax is not licensed for people who have had prior episodes of shingles because that 
population was not included in the Shingles Prevention Study. As a result, some health plans are not 
providing the vaccine to adults who have had shingles. For example, in its information for members, 
Kaiser Permanente for northern California states, “The U.S. FDA does not recommend this shot for 
people who have already had shingles.” 
 In reaching its recommendation, the ACIP determined that a reoccurrence of shingles is not as 
rare as was once thought, and it would be too burdensome for providers to determine if a patient had a 
prior episode of confirmed shingles, Dr. Harpaz with CDC noted. “We thought it would be a big barrier to 
using the vaccine” if patients had to be screened for a prior shingles episode, Dr. Harpaz said of the 
ACIP’s decision.  
 Dr. Oxman, who chaired the Shingles Prevention Study conducted at 22 sites, said the FDA’s 
package insert does not mention that the incidence of postherpetic neuralgia was reduced by 67% in the 
study. “The vaccine’s most important characteristic is its ability to reduce by two-thirds the incidence of 
clinically significant postherpetic neuralgia, which is responsible for much of the morbidity of shingles in 
older adults,” he said. Because the FDA did not include that data, the package label identifies only a 39% 
reduction in pain in those who developed PHN despite receiving the vaccine. The FDA concentrated on 
the risk of people developing PHN once they had shingles, “which was not a study endpoint,” according 




“CDC needs to try to translate the technical information into simple-to- 
understand information for practicing physicians and for the public.”  
— Dr. Walter Orenstein, former head of CDC’s immunization program 
 
 CDC’s role is to make public health professionals and the public aware of the vaccine and to 
work to reduce any disparities in health care, Dr. Harpaz said. “Our focus should be on enabling use of 
shingles vaccine, including educating providers, educating the public and reducing barriers to the 
availability of the vaccine, such as the financing and the storage/handling issues,” Dr. Harpaz said. 
 A CDC workgroup for the shingles vaccine has collaborated with CDC’s Healthy Aging Program 
to educate professionals about the shingles vaccine, CDC’s Lindley said. That partnership will help funnel 
information to the aging services network, consisting of state and local area agencies on aging, Indian 
programs that work with older adults, and service providers, as well as the Administration on Aging. 
 The recent addition of zoster immunization for all adults 60 years of age or older to the Adult 
Immunization Schedule also should help increase awareness among physicians. 
 In response to focus groups conducted with state immunization program managers, CDC 
developed some basic information on Zostavax so that immunization managers could update their 
materials, Lindley said. CDC also offers “Immunization Updates” via satellite broadcasts four times a 
year. These updates address storage and handling concerns and other questions that providers might have. 
The vaccine also is discussed at conferences and educational meetings for professionals on vaccine 
preventable diseases, said Gina Mootrey, DO, MPH, a medical epidemiologist, with CDC’s National 
Center for Immunization and Respiratory Diseases. CDC’s vaccine/shingles website 
(http://www.cdc.gov/vaccines/vpd-vac/shingles/default.htm) has a Q&A section on shingles vaccine, as 
well as slide sets from provider education sessions.  
 Disease tracking and monitoring (surveillance), often referred to as the “bread and butter” of 
CDC, also is important. Surveillance and epidemiological studies are ongoing throughout the year and 
information from these studies is presented at various conferences and in publications, Lindley said. The 
Varicella Active Surveillance Project (VASP), a CDC cooperative agreement with the Philadelphia 
Department of Public Health and the Los Angeles County Department of Health Services, collects 
population-based incidence rates for herpes zoster diseases in their communities. VASP monitoring had 
traditionally focused on those age 20 or younger, but CDC is moving to expand the surveillance to adults 
age 50 or older, Dr. Harpaz said.  
 Other CDC monitoring efforts include placing questions about shingles on various surveys, 
including the Health and Retirement Study and the National Health Interview Survey, Dr. Harpaz said. 
CDC is exploring the possibility of collecting shingles information through the Behavioral Risk Factor 
Surveillance System and the Vaccine Safety Datalink, a collaborative project with managed care 
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organizations to collect medical and immunization histories for more than 5.5 million people annually. 
CDC also would like to use Medicare data on shingles to help monitor trends. 
 
FUTURE DIRECTIONS  
 The success of any preventive vaccine program hinges on both public and physician education 
about the importance of vaccination. This is especially true because older adults are less likely to have a 
“well patient” visit when preventive measures might be considered. Clearly more public education is 
needed to ensure older adults and their caregivers are aware of the seriousness of shingles and its 
complications, and the importance of vaccination. Another prime area for education is vaccination 
reimbursement policy. “The best thing that could be done is for people to know if their insurance would 
fully cover the cost of this vaccine for them,” Lindley said. 
 CDC needs to continue to conduct surveillance and measure immunization coverage, work to 
minimize barriers to access, monitor vaccine use and impact, and track adverse events, said Dr. Orenstein, 
who is a former director of CDC’s National Immunization Program (now part of the National Center for 
Immunization and Respiratory Diseases).  
 MedPAC, an independent federal body that advises Congress on Medicare issues, has suggested 
that Congress should permit coverage for appropriate preventive vaccines under Medicare Part B instead 
of Part D. “If beneficiaries have to pay the full payment rate for vaccines and then seek reimbursement 
from their plans, physicians are concerned that the out-of-pocket cost will discourage beneficiaries from 
seeking preventive care,” MedPAC told Congress in 2007. Putting all vaccines under Part B would 
increase Medicare spending “by less than $50 million for one year and by less than $1 billion over five 
years,” according to MedPAC’s data. By comparison, Medicare’s overall health care expenditures were 
$408 billion in 2006, according to the latest report from the Medicare Trustees. 
 Ongoing research also will determine future policy decisions, such as possibly lowering the 
recommended age for vaccination to 50, providing a “booster shot” at some time after the initial 
vaccination, using a higher dose of vaccine or allowing vaccination of people with some degree of 
immunosuppression. 
 The duration of the vaccine’s effectiveness over time in an individual is still unknown, because 
the vaccine is relatively new and immunity continues to decline with age. At present, the vaccine’s 
effectiveness has continued for the four years that the original study participants have been followed to 
date. If further research indicates that immunity fades over time, then a second vaccine, or “booster shot,” 
may be recommended. Dr. Schmader said, “My gut feeling is that the cell-mediated immunity gains that 
we get with the vaccine are going to decline in older individuals, so that there probably will be a need for 
a booster at some point.” 
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 Additional safety data for Zostavax will be analyzed after completion of a 10-year extension of 
the Shingles Prevention Study (in a study population of 7,000 people vaccinated under the initial 
program). “Merck plans to pursue an indication for people between 50 and 59 years of age” as well, Dr. 
Benson added. Other studies will evaluate the use of Zostavax concomitantly with other adult vaccines, 
Merck said. Merck also has committed to study the safety of high-dose Zostavax in approximately 5,000 
people and the safety of Zostavax in about 300 people on low-to-moderate doses of steroids.  
 The Zostavax vaccine could be the start of something big in the adult vaccine world. “This is the 
start of a cutting edge for adult vaccines,” Dr. Schmader suggested. “We’ve had a paucity of research on 
vaccines for older adults in general. In the pediatric world, it seems we have had many more new 
vaccines.” Dr. Schmader pointed out that the pharmaceutical company Sanofi-Pasteur is testing a new 
tetanus and acellular pertussis vaccine for adults. Also, a new pneumococcal conjugate vaccine, different 
from the present pneumonia vaccine, is going to be investigated in the elderly, he said. There also is 
interest in developing a staph aureus vaccine against antibiotic-resistant staph infections. 
 Future policy directions may include guidance on shingles vaccination for nursing homes and 
other institutions where seniors live. “It is explicitly noted in the ACIP recommendations that nursing 
homes and other institutions should not fall through the cracks,” Dr. Harpaz said. “ACIP said that 
providers should be mindful of vaccinating such populations if it is medically appropriate for them.”  
This document is available online at www.chronicdisease.org and at 
www.cdc.gov/vaccines/news/media.htm#Reporters.  It was written by Nancy Aldrich. William F. Benson 




STORY IDEAS FOR JOURNALISTS 
1) Find someone in your area who has had complications of postherpetic neuralgia and describe the 
impact on daily living and quality of life. What is the impact on family caregivers of frail individuals with 
shingles? Motivate older adults to talk to their physicians about getting vaccinated against shingles. 
 
2) Interview health care providers in your area with a particular interest in shingles (a neurologist, 
dermatologist, infectious disease specialist or pain management physician). 
 
3) Contact your local or state health department and find out if they offer Zostavax vaccine. Who pays for 
it? Are Medicare Part D prescription drug plans in your area covering the vaccine as they are required to? 
Are older adults without insurance accessing the vaccine? Find out if your state Medicaid plan covers 
Zostavax for adults between ages 60 and 64.  
 
4) Check with the local aging network (e.g., area agencies on aging) and public health officials to see if 
they are doing education and raising awareness about shingles and Zostavax. 
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